Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beauvechain – page 2

1 944 clinical trials in Beauvechain, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beauvechain at a glance
1 944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 944 trials in Beauvechain

Open in trial search

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Narcolepsy

Recruiting

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Vitiligo

Recruiting

Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY4005130
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

Obesity+1

Recruiting

A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beauvechain

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management strategies in primary care settings. The studies examine optimal approaches for patients with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Strategies
  • Gastrointestinal Health Management
  • Primary Care Interventions

Investigations compare different therapeutic approaches, including on-demand medication use and alternative treatments, to improve long-term patient outcomes in acid-related disorders.

02 Primary Care Medicine

Studies evaluating the effectiveness of various medication discontinuation protocols for patients with chronic heartburn and related conditions. Research aims to establish optimal treatment pathways.

  • Medication Management
  • Patient-Centered Care
  • Treatment Optimization

The research explores alternative therapeutic options and their impact on patient well-being and quality of life.

03 Digestive Health

Clinical investigations examining the management of acid reflux and related conditions through various therapeutic approaches, including traditional and alternative treatment methods.

  • Symptom Management
  • Alternative Therapies
  • Long-term Care Strategies

Research focuses on developing evidence-based approaches for medication reduction while maintaining optimal symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.